Apollomics Inc. Class A Ordinary Shares (APLM) stock: key figures, P/E, revenue and dividend
Health Care · Biotechnology · United States · ISIN KYG0411D1236
Apollomics Inc. Class A Ordinary Shares financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 198,000.00 USD | 8.50 m USD |
| Gross profit | 198,000.00 USD | 8.25 m USD |
| Operating income | -42.14 m USD | -9.47 m USD |
| EBIT | -41.13 m USD | -9.47 m USD |
| Net income | -53.86 m USD | -10.94 m USD |
| Diluted EPS – continuing operations | -58.13 USD | -7.57 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Apollomics Inc. Class A Ordinary Shares
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to inhibit cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer and other solid tumors with MET dysregulation; and APL-102, an oral active, small molecule multiple tyrosine kinase inhibitor, which is in a in a Phase 1 clinical trial for cancer treatment. It also develops immuno-oncology products, such as APL-501, an anti-PD-1 antibody product candidate, which is in phase 1 clinical trial for the treatment of advanced or relapsed/refractory solid tumors; APL-502, an anti-PD-L1 antibody product candidate for the treatment of tumors; APL-810, a novel, rationally designed, ACCI recombinant vaccine for the treatment of gastrin immunogen; and APL-801, a CD40 and PD-L1 antibody product candidate for the treatment of tumors. The company was founded in 2015 and is based in Foster City, California.
More stocks
- FAST CASUAL CONCEPTS, INC. (FCCI)
- Kns Co., Ltd (432470.KQ)
- Marpai, Inc. (MRAI)
- Telcoware (078000.KS)
- Dongbang Trans (004140.KS)
- iBio, Inc. (IBIO)
- Chain Chon Industrial Co Ltd (5014.TWO)
- Eminent Luggage Corporation (9950.TWO)
- Hyperfine, Inc. (HYPR)
- Shan-Loong Transportation Co Ltd (2616.TW)
- DreamCIS Inc (223250.KQ)
- Byuksan Corp (007210.KS)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.